Three facts indicate that SGLT2 inhibitors may be effective in treating renal anemia, although anemia is resistant to treatment with erythropoiesis-stimulating agents; the hematocrit and hemoglobin levels increased after SGLT2 therapy in patients whose eGFR had already decreased; greater elevations of hemoglobin and hematocrit were observed in patients with lower corresponding baseline values; and SGLT2 inhibitors improve iron utilization. The gene discussed is SLC5A2; the disease is anemia.